Navigation Links
Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium
Date:12/14/2008

rence is 'low' or 'high'," said Dr. Sgroi. "The ability to reduce the number of patients in the 'intermediate' group by reclassifying them as either 'high' or 'low' risk, making risk prediction more specific, should go a long way in helping medical professionals select the most appropriate therapy for each of their patients."

On Saturday, Matthew Goetz, M.D., from Mayo Clinic and colleagues from Austria presented data examining the predictive utility of CYP2D6 and the prognostic utility of the Theros Breast Cancer Index in women with breast cancer randomized to receive five years of treatment with tamoxifen or two years of tamoxifen followed by three years anastrozole treatment. The researchers found that the Theros Breast Cancer Index will identify, among patients with early stage breast cancer, those with a higher risk of treatment failure when treated only with hormonal therapy. They concluded that the Theros Breast Cancer Index identified approximately 25 percent of grade 1 and grade 2 breast cancers that had a nearly three-fold higher risk for a subsequent recurrence in distant organs.

Finally, data from a study presented on Sunday by Olle Stal, PhD, and colleagues from Linkoping University in Sweden explored the value of the HOXB13 gene in predicting benefit of tamoxifen therapy. Researchers reviewed HOXB13 protein expression in tumor samples from 866 patients with estrogen- receptor positive tumors. Patients whose tumors expressed no or low levels of HOXB13 had a clear benefit from tamoxifen in terms of longer distant recurrence-free survival. Patients with a high or intermediate HOXB13 expression did not experience a distant recurrence-free survival benefit from tamoxifen as compared to untreated patients.

"Data from these studies reinforce clinical and research experience to date which has shown that the Theros Breast Cancer Index is an excellent test for assessing breast cancer risk prognosi
'/>"/>

SOURCE bioTheranostics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
3. Versatility of 454 Sequencing(TM) Demonstrated in Three Publications in Science Last Week
4. Data from Three Clinical Trials for Perforomist(TM) Inhalation Solution to be Presented at CHEST 2007 on October 24, 2007
5. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
6. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
7. Despite Serious Health Risks, One in Three Adults with Heart Disease Does Not Believe They Need a Flu Shot This Year
8. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
9. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
10. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
11. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... from institutional investors to purchase an aggregate of approximately ... at-the-market registered direct offering, led by a dedicated health ... purchase agreements with these investors pursuant to which the ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) announces that ... to the announced tender offer for all of the outstanding shares ... of the waiver, the transaction is no longer conditional on OFT ... 24, 2014 following the currently scheduled expiration time, subject to the ...
(Date:1/15/2014)... 15, 2014 BreedIT Corp (OTC: BRDT), ... distributor of highly sophisticated agro-breeding solutions for plant breeders ... the Company,s board of directors appointed chemistry and pharmaceutical ... new member of the board. From 1975 ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... LAKE CITY, Jan. 28, 2011 TechniScan (OTC Bulletin ... engaged in the development and commercialization of an automated ... Robinson, Chief Executive Officer, will present at RetailInvestorConferences.com. DATE: ... ESTLINK: , www.retailinvestorconferences.com This will be a live, ...
... BioSciences, Inc. (NasdaqCM: DARA), a biopharmaceutical development company ... through proof of concept in humans for subsequent ... today that Richard Franco, CEO, will present at ... 5:00 PM ESTLINK: , www.retailinvestorconferences.com This will ...
Cached Medicine Technology:TechniScan to Present Live, Online at RetailInvestorConferences.com on February 3rd 2DARA BioSciences to Present Live at RetailInvestorConferences.com on February 3 2DARA BioSciences to Present Live at RetailInvestorConferences.com on February 3 3
(Date:4/17/2014)... NEW YORK, NY (April 16, 2014) The cause ... but a new study proposes that neurons may be ... own immune system, similar to the way autoimmune diseases ... attack the body,s cells. The study was published April ... is a new, and likely controversial, idea in Parkinson,s ...
(Date:4/17/2014)... Irvine, Calif., April 17, 2014 By discovering a ... immediately after a stroke, researchers at UC Irvine and ... therapies that may limit or prevent stroke-induced brain damage. ... the fourth-leading cause of death and primary reason for ... damaged in a stroke and lets blood-borne material into ...
(Date:4/17/2014)... 2014 EcoHealth Alliance, a nonprofit organization that focuses ... comprehensive review today examining the current state of knowledge ... calls for improved global surveillance strategies to combat the ... of Ebola in West Africa that has claimed the ... and Liberia. According to the World Health Organization ...
(Date:4/17/2014)... potential to ward off depression among retirees, particularly among ... in The Journals of Gerontology, Series B: ... article " Internet Use and Depression Among Retired Older ... the authors report that Internet use reduced the probability ... study sample. , Late-life depression affects between 5 ...
(Date:4/17/2014)... Population Council scientists and their partners have found that ... prevent the transmission of multiple sexually transmitted infections (STIs) ... herpes simplex virus 2 (HSV-2), and human papillomavirus (HPV). ... the gel is effective against multiple strains of HIV, ... against all three viruses of at least eight hours ...
Breaking Medicine News(10 mins):Health News:Is Parkinson's an autoimmune disease? 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Internet use may cut retirees' depression 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2
... the disparity need to be further explored, researchers say ... health insurance are more likely to die after admission ... are insured, new research suggests. , "After admission ... based on insurance status," the study authors wrote. "This ...
... , HUNTINGTON BEACH, Calif., Nov. 17 With ... to spend on holiday gifting this year. Imagine being ... offers relief to tired and overworked feet. Yoga Sandals® ... slippers that help keep feet flexible with 20% of each ...
... ... XOWii Thin. XOWii,s first product, XOWii Energy, which was launched in early October, has ... never-before-seen product that delivers whole-food nutrition and contributes to healthy weight control. , ... (PRWEB) November 16, 2009 --The XOWii company ...
... , ... documents how a simple spice from India has for more than 3500 years been inhibiting ... Turmeric Research Report" also shares how stem cells are currently being used to treat more ... ...
... , States Take Action to ... 17 For the second consecutive year, the United States earned ... Card, demonstrating that more than half a million of our nation,s ... 2009 Premature Birth Report card, seven states improved their performance by ...
... AdCare Health Systems, Inc. (NYSE AMEX: ADK ), ... company, today reported financial results for its third quarter of ... were $6,909,499 as compared to $6,185,760 for the same quarter ... due to better occupancy at our skilled nursing centers and ...
Cached Medicine News:Health News:Uninsured Trauma Patients More Likely to Die: Study 2Health News:Give a Gift that Gives Back With Yoga Sandals(R) Comfys 2Health News:XOWii Launches Second Product in its Line of What are Proving to be Impeccably Designed and Unique Products 2Health News:Turmeric-The Scientific Evidence How It Prevents And Treats Cancer & Dementia 2Health News:Turmeric-The Scientific Evidence How It Prevents And Treats Cancer & Dementia 3Health News:Turmeric-The Scientific Evidence How It Prevents And Treats Cancer & Dementia 4Health News:U.S. Gets a 'D' for Preterm Birth Rate 2Health News:U.S. Gets a 'D' for Preterm Birth Rate 3Health News:AdCare Health Systems, Inc. Reports 2009 Third Quarter Earnings Results; Third Consecutive Profitable Quarter 2Health News:AdCare Health Systems, Inc. Reports 2009 Third Quarter Earnings Results; Third Consecutive Profitable Quarter 3Health News:AdCare Health Systems, Inc. Reports 2009 Third Quarter Earnings Results; Third Consecutive Profitable Quarter 4Health News:AdCare Health Systems, Inc. Reports 2009 Third Quarter Earnings Results; Third Consecutive Profitable Quarter 5Health News:AdCare Health Systems, Inc. Reports 2009 Third Quarter Earnings Results; Third Consecutive Profitable Quarter 6Health News:AdCare Health Systems, Inc. Reports 2009 Third Quarter Earnings Results; Third Consecutive Profitable Quarter 7Health News:AdCare Health Systems, Inc. Reports 2009 Third Quarter Earnings Results; Third Consecutive Profitable Quarter 8Health News:AdCare Health Systems, Inc. Reports 2009 Third Quarter Earnings Results; Third Consecutive Profitable Quarter 9Health News:AdCare Health Systems, Inc. Reports 2009 Third Quarter Earnings Results; Third Consecutive Profitable Quarter 10
... system is especially designed to accomodate the ... as a double work station. The ... can be positioned on the top or ... blower and filter information, please see link ...
... The HypercleanTM 2 ... especially for enclosing benchtop equipment. ... can fit comfortably inside the ... 2 fume containment system unit ...
... Shandon Hyperclean 20 fume containment system ... with a swing-down front panel hinges ... the front opening. The sides ... acrylic which is impervious to most ...
Reusable shielded cable...
Medicine Products: